International Journal of Molecular Sciences (Dec 2019)

Design, Synthesis and Molecular Modeling Study of Conjugates of ADP and Morpholino Nucleosides as A Novel Class of Inhibitors of PARP-1, PARP-2 and PARP-3

  • Yuliya V. Sherstyuk,
  • Nikita V. Ivanisenko,
  • Alexandra L. Zakharenko,
  • Maria V. Sukhanova,
  • Roman Y. Peshkov,
  • Ilia V. Eltsov,
  • Mikhail M. Kutuzov,
  • Tatiana A. Kurgina,
  • Ekaterina A. Belousova,
  • Vladimir A. Ivanisenko,
  • Olga I. Lavrik,
  • Vladimir N. Silnikov,
  • Tatyana V. Abramova

DOI
https://doi.org/10.3390/ijms21010214
Journal volume & issue
Vol. 21, no. 1
p. 214

Abstract

Read online

We report on the design, synthesis and molecular modeling study of conjugates of adenosine diphosphate (ADP) and morpholino nucleosides as potential selective inhibitors of poly(ADP-ribose)polymerases-1, 2 and 3. Sixteen dinucleoside pyrophosphates containing natural heterocyclic bases as well as 5-haloganeted pyrimidines, and mimicking a main substrate of these enzymes, nicotinamide adenine dinucleotide (NAD+)-molecule, have been synthesized in a high yield. Morpholino nucleosides have been tethered to the β-phosphate of ADP via a phosphoester or phosphoramide bond. Screening of the inhibiting properties of these derivatives on the autopoly(ADP-ribosyl)ation of PARP-1 and PARP-2 has shown that the effect depends upon the type of nucleobase as well as on the linkage between ADP and morpholino nucleoside. The 5-iodination of uracil and the introduction of the P−N bond in NAD+-mimetics have shown to increase inhibition properties. Structural modeling suggested that the P−N bond can stabilize the pyrophosphate group in active conformation due to the formation of an intramolecular hydrogen bond. The most active NAD+ analog against PARP-1 contained 5-iodouracil 2ʹ-aminomethylmorpholino nucleoside with IC50 126 ± 6 μM, while in the case of PARP-2 it was adenine 2ʹ-aminomethylmorpholino nucleoside (IC50 63 ± 10 μM). In silico analysis revealed that thymine and uracil-based NAD+ analogs were recognized as the NAD+-analog that targets the nicotinamide binding site. On the contrary, the adenine 2ʹ-aminomethylmorpholino nucleoside-based NAD+ analogs were predicted to identify as PAR-analogs that target the acceptor binding site of PARP-2, representing a novel molecular mechanism for selective PARP inhibition. This discovery opens a new avenue for the rational design of PARP-1/2 specific inhibitors.

Keywords